Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + ramucirumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Durvalumab + ramucirumab is an investigational combination therapy consisting of two monoclonal antibodies: durvalumab, an anti–PD-L1 IgG1 antibody (marketed as Imfinzi), and ramucirumab, an anti–VEGFR2 IgG1 antibody (marketeted as Cyramza). Durvalumab blocks the interaction of PD-L1 with PD-1 and CD80, enhancing T-cell mediated immune responses against tumor cells. Ramucirumab inhibits vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking angiogenesis required for tumor growth. The combination aims to enhance antitumor activity by simultaneously targeting immune evasion and tumor angiogenesis pathways. It has been studied in phase I trials for advanced/metastatic non-small-cell lung cancer (NSCLC), gastric/gastro-esophageal junction adenocarcinoma, and hepatocellular carcinoma after prior therapies[1][3][7].
- Brand names
- CyramzaImfinzi
- Other names
- durvalumab plus ramucirumabramucirumab/durvalumab combination
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on durvalumab + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + ramucirumab.